
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$37.22
−US$1.08 · -2.82%
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
一般交易時段
US$37.22
−US$1.08 · -2.82%
盤中時間採用ET。市場資料可能有所延遲。
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
日內區間
目前US$37.22
52週區間
目前US$37.22
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
87
深度低估
情緒
41
多空交錯
風險
57
風險偏高
動能
27
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
日內區間
目前US$37.22
52週區間
目前US$37.22
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | 15.18億 USD | 12.96億 USD | 10.18億 USD | 9.78億 USD | 9.42億 USD |
| 銷貨成本 | 10.06億 USD | 8.96億 USD | 7.05億 USD | 6.8億 USD | 6.57億 USD |
| 毛利 | 5.12億 USD | 4億 USD | 3.13億 USD | 2.98億 USD | 2.85億 USD |
| 銷售、一般及管理費用 | 3.13億 USD | 2.89億 USD | 2.6億 USD | 2.26億 USD | 2.06億 USD |
| 營業費用 | 3.13億 USD | 2.89億 USD | 2.6億 USD | 2.26億 USD | 2.06億 USD |
| 利息收入 | 145.9萬 USD | 262.2萬 USD | 447.4萬 USD | 335.5萬 USD | 81.6萬 USD |
| 利息支出 | 4760.4萬 USD | 3324.9萬 USD | 2197萬 USD | 1794.9萬 USD | 1210.1萬 USD |
| 折舊和攤銷 | 5151.4萬 USD | 4560.5萬 USD | 3617.8萬 USD | 3401.2萬 USD | 3270.5萬 USD |
| 營業利益 | 1.98億 USD | 1.1億 USD | 5331.5萬 USD | 7184.7萬 USD | 7898.6萬 USD |
| 淨利 | 9972萬 USD | 4826.4萬 USD | 241.6萬 USD | 3260.6萬 USD | 4917.5萬 USD |
公司資料更新於 2026年10月12日。
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$28.00
下跌空間 24.77%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2489.43萬0.00%2.3兆 USD0.03%US$381.1-0.22%
iShares Russell 2000 ETFIWM2130.2萬0.03%787.4億 USD0.19%US$277.92-0.37%
Vanguard Extended Market ETFVXF925.37萬0.01%954億 USD0.05%US$233.53-0.63%
iShares Russell 2000 Growth ETFIWO747.75萬0.05%139.17億 USD0.24%US$353.71-0.86%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM743.91萬0.05%158.4億 USD0.03%US$53.485+0.07%
Dimensional - US Small Cap ETFDFAS607.09萬0.02%338.69億 USD0.31%US$78.2501-0.13%
State Street SPDR S&P Pharmaceuticals ETFXPH582.02萬1.26%4.62億 USD0.35%US$64.12-0.82%
State Street SPDR S&P 600 Small Cap Growth ETFSLYG470.54萬0.10%47.76億 USD0.15%US$108.4-0.16%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
Dimensional - US Small Cap ETFDFAS
State Street SPDR S&P Pharmaceuticals ETFXPH
State Street SPDR S&P 600 Small Cap Growth ETFSLYGAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。